Veru Inc.

Passed

Offering Date:
common stock between May 11, 2022, and November 9, 2022

Lead Plaintiff Deadline:
February 06, 2023

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.

First Name

Last Name

Phone

Street Address

City

State

Zip

Shares Purchased

Purchase Date

Estimated Loss

The submission of this form does not create an attorney-client relationship.

Allegations

1) the Company had withheld material adverse facts about the data from the sabizabulin Phase 3 trial and the Company’s interactions with the United States Food and Drug Administration; 2) defendants misled Veru's shareholders to believe that the data from the sabizabulin Phase 3 trial was sufficient to support Emergency Use Authorization (“EUA”) and even the submission of a New Drug Application without any further studies; and 3) the Company's filings concealed the true risks faced by Veru in gaining approval for its EUA request.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of purchased or acquired during the class period listed above and/or pursuant to the stock offering(s) referenced above.

Lead Plaintiff Deadline

If you suffered a loss in during the relevant time frame or pursuant to the relevant offering(s), you have until February 06, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.